key: cord-1027704-ldy5oyxc
authors: Wang, Deng-chao; Yu, Miao; Xie, Wen-xian; Huang, Li-yan; Wei, Jian; Lei, Yue-hua
title: Meta-analysis on the effect of combining lianhua qingwen with western medicine to treat coronavirus disease 2019
date: 2021-11-02
journal: J Integr Med
DOI: 10.1016/j.joim.2021.10.005
sha: 242a77722b9c484a1d8184011291cf4af66eccbd
doc_id: 1027704
cord_uid: ldy5oyxc

Background Coronavirus disease 2019 (COVID-19) has become a worldwide life-threatening pandemic. Lianhua Qingwen is believed to possess the ability to treat or significantly improve the symptoms of COVID-19. These claims make it important to systematically evaluate the effects of using Lianhua Qingwen with Western medicine to treat COVID-19. Objective To evaluate the safety and efficacy of combination therapy, employing Lianhua Qingwen with Western medicine, to treat COVID-19, using a meta-analysis approach. Search strategy China National Knowledge Infrastructure, Wanfang Database, VIP Database, PubMed, Embase, and Cochrane Library databases were searched for studies evaluating the effect of Lianhua Qingwen-Western medicine combination therapy in the treatment of COVID-19. Inclusion criteria (1) Research object: hospitalized patients meeting the diagnostic criteria of COVID-19 were included. (2) Intervention measures: patients in the treatment group received Lianhua Qingwen treatment combined with Western medicine, while the control group received either Western medicine or Chinese medicine treatment. (3) Research type: randomized controlled trials and retrospective study were included. Data extraction and analysis Two researchers extracted the first author, the proportion of males and females, age, body temperature, course of treatment, rate of disappearance of main symptoms, duration of fever, adverse reactions, and total effectiveness from the literature. Odds ratio (OR) and 95% confidence interval (CI) were used as the effect value for count data, and mean difference (MD) and 95% CI were used as the effect value for measurement data. Results Six articles met the inclusion criteria, including a total of 856 COVID-19 patients. The meta-analysis showed that Lianhua Qingwen combination therapy achieved higher rates of fever reduction (OR = 3.43, 95% CI [1.78, 6.59], P = 0.0002), cough reduction (OR = 3.39, 95% CI [1.85, 6.23], P < 0.0001), recovery from shortness of breath (OR = 10.62, 95% CI [3.71, 30.40], P < 0.0001) and recovery from fatigue (OR = 2.82, 95% CI [1.44, 5.53], P = 0.003), higher total effectiveness rate (OR = 2.51, 95% CI [1.73, 3.64], P < 0.00001), and shorter time to recovery from fever (MD = –1.00, 95% CI [–1.04, 0.96], P < 0.00001), and did not increase the adverse reaction rate (OR = 0.65, 95% CI [0.42, 1.01], P = 0.06), compared to the single medication control. Conclusion The Lianhua Qingwen and Western medicine combination therapy is highly effective for COVID-19 patients and has good clinical safety. As only a small number of studies and patients were included in this review, more high-quality, multicenter, large-sample-size, randomized, double-blind, controlled trials are still needed for verification.

Coronavirus disease 2019 , characterized by acute respiratory tract symptoms, is caused by a novel coronavirus, "2019-nCoV," and has become a global pandemic [1, 2] . Common symptoms of the disease include fever, shortness of breath, fatigue, and cough; however, severely and critically ill patients can experience life-threatening respiratory failure and renal failure [3] . Conventional Western medicine, taken in conjunction with traditional Chinese medicine, has played a significant role in the resolution of these symptoms [4] [5] [6] . Lianhua Qingwen is believed to be able to treat COVID-19 and to improve its symptoms, including cough, fever, and fatigue [7] . The underlying mechanism may be a combination of broad-spectrum antibacterial, antiviral, and antipyretic activities that contribute to relieving cough, reducing phlegm, and regulating immunity [8] [9] [10] [11] . In this study, a systematic approach was used to search for clinical trials and to evaluate the efficacy of Lianhua Qingwen taken in combination with Western medicine for the treatment of COVID-19; our conclusions include relevant evidence-based medical advice. (1) Research objects: hospitalized patients meeting the diagnostic criteria of "Diagnosis and treatment of COVID-19" [12] were included. (2) Intervention measures: patients in the treatment group received a combination of Lianhua Qingwen and Western medicine treatment, while control group received either Western or Chinese medicine treatment. (3) Research type: randomized controlled trial (RCT) and retrospective study. (4) Outcome indicators: the disappearance rate of main symptoms, duration of fever, adverse reactions, and total effectiveness rate were recorded.

Studies returned in the search were excluded from this meta-analysis if they were duplicates of other literature, case reports, or reviews; if they had had incomplete or unavailable outcome indicators; if they had no control group; and if their study population excluded critically ill patients.

Initially, a total of 71 studies were retrieved from the databases, and one was manually retrieved. By reading the titles and abstracts, it was determined that 25 were duplicate studies, 13 were irrelevant to the research purpose, 23 were reviews, and 3 were case studies; these were all excluded. The remaining eight articles were re-screened after reading the full text; one study without a control group and one study with basic research were excluded. After the above step-by-step screening, 6 studies [15] [16] [17] [18] [19] [20] were finally included. The screening process is illustrated in Fig. 1 . The data extracted from the included studies are shown in Table 1 . All the results are summarized in Table 2 . 

The two RCTs [16, 20] had a Jadad score of 4 and 6, respectively, while the 4 retrospective studies [15, [17] [18] [19] each had a NOS score of 7. These were all high-quality studies and were comparable at baseline.

Two studies [16, 20] were RCTs. Both [16, 20] explained their method of randomization; one study [16] described the concealment of allocation and blinding methods, and the other [20] did not. The data from the two studies [16, 20] were complete, and the selective reporting of research results and other sources of bias were not mentioned. The bias risk assessment is shown in Fig. 2 and the risk of bias summary in Fig. 3 . 

Four studies [15] [16] [17] 19] compared the time to recovery from fever between the combination therapy group and the single medication group. There was no statistical heterogeneity between the studies (P = 0.78, I 2 = 0%), and a fixed effects model was used to combine the effect sizes for analysis. The combination therapy group had significantly shorter time to recovery from fever in the treatment of COVID-19 than the single medication group (MD = -1.00, 95% CI [-1.04, 0.96], P < 0.00001; Fig. 4 ). 

Three studies [15, 18, 19] compared the rate of recovery from fever between the combination therapy group and the control. The average rates of recovery from fever in the combination therapy group and the control group were 85.5% (106/124) and 62.5% (60/96), respectively. No statistical heterogeneity was observed among the included studies (P = 0.92, I 2 = 0%), and a fixed effects model was used to combine the effect sizes for analysis. We found that the combination therapy group had a significantly higher rate of recovery from fever than the control group in the treatment of COVID-19 (OR = 3.43, 95% CI [1.78, 6.59], P = 0.0002; Fig. 5 ).

Comparison of the rate of recovery from fever between the two groups.

Three studies [15, 18, 19] compared the rate of recovery from cough between the combination therapy group and the control group. The rates of recovery from cough of the combination therapy group and the control group were 56.6% (60/106) and 27.9% (26/93), respectively. No statistical heterogeneity was seen among the studies (P = 0.39, I 2 = 0%), and a fixed effects model was used to combine the effect sizes for analysis. We found that the combination therapy group had a significantly higher rate of recovery from cough than the single medication group in the treatment of COVID-19 (OR = 3.39, 95% CI [1.85, 6.23], P < 0.0001; Fig. 6 ). Fig. 6 . Comparison of the rate of recovery from cough between the two groups.

Three studies [15, 18, 19] compared the recovery rate of shortness of breath between the combination therapy group and the single medication group. The rates of recovery from shortness of breath in the combination therapy group and the single medication group were 68.2% (30/44) and 15.4% (6/39), respectively. No statistical heterogeneity was observed among the studies (P = 0.75, I 2 = 0%), and a fixed effects model was used to combine the effect sizes for analysis. We found that the combination therapy group had a significantly higher rate of recovery from shortness of breath than the single medication group in the treatment of COVID-19 (OR = 10.62, 95% CI [3.71, 30 .40], P < 0.0001; Fig. 7 ).

Comparison of the rate of recovery from shortness of breath between the two groups.

Three included studies [15, 18, 19] compared the rate of recovery from fatigue between the combination therapy group and the control group. The rates of recovery from fatigue in the combination group and the control group were 68.7% (57/83) and 42.8% (33/77), respectively. There was no statistical heterogeneity among the studies (P = 0.76, I 2 = 0%), and a fixed effects model was used to combine the effect sizes for analysis. We found that that the combination therapy group had a significantly higher rate of recovery from fatigue than the single medication group in the treatment of COVID-19 (OR = 2.82, 95% CI [1.44, 5.53], P = 0.003; Fig. 8 ). 

Three included studies [16, 18, 20] compared adverse reactions to the treatment between the combination therapy group and the control group. The incidences of adverse reactions in the combination therapy group and the control group were 21.3% (68/319) and 26.6% (85/320), respectively. No statistical heterogeneity could be seen between the studies (P = 0.27, I 2 = 17%), and a fixed effects model was used to combine the effect sizes for analysis. We found that there was no significant difference in the incidence of adverse reactions between the combination therapy group and the single medication group in the treatment of COVID-19 (OR = 0.65, 95% CI [0.42, 1.01], P = 0.06; Fig. 9 ). Fig. 9 . Comparison of the incidence of adverse reactions between the two groups.

Four studies [15, 16, 18, 20] compared the total effectiveness rate between the combination therapy group and the control group. The total effectiveness rates of the combination therapy group and the control group were 85.4% (316/370) and 70.6% (262/371), respectively. No statistical heterogeneity was seen between the different studies (P = 0.87, I 2 = 0%), and a fixed effects model was used to combine the effect sizes for analysis. We found that the combination therapy group had a significantly higher total effectiveness rate in the treatment of COVID-19 than the control group (OR = 2.51, 95% CI [1.73, 3.64], P < 0.00001]; Fig. 10 ). 

The global COVID-19 pandemic has become increasingly severe, and it has been listed by the World Health Organization as a "public health emergency of international concern" [21, 22] . COVID-19 can be classified as an "epidemic" in Chinese medicine [23] . Lianhua Qingwen capsules contain a traditional Chinese medicine preparation. It is composed of 13 Chinese medicine extracts, namely, forsythia, honeysuckle, ephedra, wood fern, Isatis root, gypsum, menthol, patchouli, rhodiola, fishwort, rhubarb, sauteed bitter almonds, and licorice [24] . It clears toxins and plays a role in regulating lung function. The drug is widely used in modern applications to treat respiratory diseases caused by viral infections [25] . Pharmacological studies have shown that Lianhua Qingwen has inhibitory effects against the severe acute respiratory syndrome virus cultured in vitro [26] , provides multistage resistance to influenza A viruses H1N1 and H3N2 [27] and inhibits avian influenza virus H7N9 [28] . Lianhua Qingwen inhibits the release of inflammatory mediators in the body, thereby ameliorating the damage to lung tissue [29] . It has antibacterial effect against secondary bacterial infections after viral infections, reduces fever, and has anti-inflammatory properties [30] [31] [32] , thereby promoting the relief of symptoms related to COVID-19. The latest network pharmacology research shows that Lianhua Qingwen can show its efficacy against coronavirus via multiple pathways, targets, and components. The active ingredients display a binding affinity to main protease and angiotensin-converting enzyme 2, and the mechanism encompasses a broad-spectrum antibacterial, antiviral and antipyretic effects, amelioration of phlegm and cough, immune regulation, suppression of virus-induced nuclear factor-κB activation and reduction in the expression of interleukin-6 (IL-6), IL-8, tumor necrosis factor-α, and interferon-inducible protein-10 genes [33, 34] .

In the present meta-analysis, 6 studies meeting the inclusion criteria were included. In total, there were 442 cases in the combination therapy group and 414 cases in the control (single medication) group. Five studies used Lianhua Qingwen in the form of granules, and one study used a capsule; 4 studies reported the course of treatment, and two studies did not report the course of treatment.

The results showed that, the total effectiveness rate of combination therapy was greater than that of the single medication control ( [35] . This study has several shortcomings. First, the number of included studies was small, and the studies were all conducted in China, so it is difficult to conduct subgroup analysis of other regions and races. Second, most of the studies were non-randomized double-blind studies, and high-quality, multicenter, large-sample-size, randomized, double-blind, controlled trials are still needed to verify the results. Third, some of the included studies did not report all of the important details, such as: there was no mention of blinding in the randomized study, and in two studies, the course of treatment was unknown.

This meta-analysis confirmed that Lianhua Qingwen, taken in combination with Western medicine can significantly improve the main symptoms of patients with COVID-19; this treatment approach is able to shorten the time to recovery from fever, has significant clinical efficacy and causes few adverse reactions. Combination therapy with Lianhua Qingwen and Western medicine was effective in patients with mild to moderate COVID-19. However, due to the few studies available, the present analysis had a small sample size, and multicenter, large-sample-size RCTs are still needed to verify the therapeutic advantages of including Chinese medicine in treatment of COVID-19.

No funding was received for this study.

DCW and MY designed this study, and WXX executed the search strategy; JW and YHL collected the data, and DCW and MY re-checked the data; JW and YHL performed the analysis, and DCW re-checked the analysis; JW and YHL assessed the quality of the studies, and DCW and MY re-checked the quality of the studies; DCW wrote the manuscript, and JW edited the manuscript. All listed authors reviewed and revised the manuscript. DCW and MY contributed equally to this work.

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status

Therapeutic management of COVID-19 patients: a systematic review

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Efficacy and safety of integrated traditional Chinese and Western medicine for corona virus disease 2019 (COVID-19): a systematic review and meta-analysis

Application and research progress of Chinese medicine in the prevention and treatment of new coronary pneumonia

Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective

Application of oral Chinese patent medicine in coronavirus disease-19

Lianhua-Qingwen displays antiviral and anti-inflammatory activity and synergistic effects with oseltamivir against influenza B virus infection in the mouse model

The clinical benefits of Chinese patent medicines against COVID-19 based on current evidence

Study on the network pharmacology and preliminary evidence of Lianhua Qingwen in the treatment of novel coronavirus (2019-nCoV)

The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan

General Office of National Health Commission of the People's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of coronavirus disease-2019

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Analysis of curative effect of 51 patients with novel coronavirus pneumonia treated with Chinese medicine Lianhua Qingwen: a multicentre retrospective study

Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb

Clinical study on combined scheme of Lianhuaqingwen capsules and abidole in the treatment for coronavirus disease

Clinical observation on Lianhua Qingwen Granules combined with Western medicine conventional therapy in the treatment of 63 suspected cases of coronavirus disease 2019

Retrospective clinical analysis on treatment of coronavirus disease 2019 with traditional Chinese medicine Lianhua Qingwen. Zhongguo Shi Yan Fang Ji Xue Za Zhi

The efficacy of Lianhua Qingwen Granules combined with abidol in the treatment of mild novel coronavirus pneumonia

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status

COVID-19 diagnostics, tools, and prevention

Progress in the prevention and control of COVID-19 by

Study of chemical components from Lianhua Qingwen Capsule (I)

Theoretical research basis and clinical efficacy of Lianhua Qingwen in treating novel coronavirus pneumonia. Shi Jie Zhong Yi Yao

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

Efficacy and safety of Lianhua Qingwen capsule for influenza: a systematic review

Antiviral effects of Lianhua Qingwen capsule against influenza virus in vitro

Efficacy and mechanism of Lianhua Qingwen capsules (LHQW) on chemotaxis of macrophages in acute lung injury (ALI) animal model

Review on the potential action mechanisms of Chinese medicines in treating coronavirus disease 2019 (COVID-19)

How can traditional Chinese medicine contribute to the therapeutic approach in coronavirus disease 2019 (COVID-19)? A review of the registered clinical trials

Identification of a pharmacological biomarker for the bioassay-based quality control of a thirteen-component TCM formula (Lianhua Qingwen) used in treating influenza A virus (H1N1) infection

The Chinese prescription Lianhuaqingwen Capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function

Exploring material basis and mechanism of Lianhua Qingwen formula against coronavirus based on network pharmacology

Literature analysis of clinical application and adverse drug reaction/event of Lianhua Qingwen capsule

The authors declare that they have no conflicts of interest.